Our findings suggest that dual-target Nrf2/ALDH2 inhibition may be well tolerated and be associated with minimal myelotoxicity, significantly enhancing sensitivity to chemotherapy drugs, providing a valuable potential target for the development of effective clinical drugs for AML treatment in the future. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.